AstraZeneca India Q1 FY26-27 Revenue Surges 30% to ₹6,828 Million
AstraZeneca Pharma India reported a 30% revenue growth to ₹6,828 million in Q1 FY26-27. Key regulatory approvals were received for Acalabrutinib and Trastuzumab deruxtecan. The company signed an MoU with the Telangana government for AI-enabled lung cancer screening and launched initiatives for hyperkalaemia management and cardiovascular care.
The strong financial performance, coupled with crucial regulatory approvals for advanced therapies and strategic collaborations, indicates a significant positive impact on the company's market position and future growth prospects.
The company reported strong revenue growth, key regulatory approvals for new treatments, and significant strategic partnerships and initiatives aimed at improving patient access and care.
AstraZeneca Pharma India Limited announced its financial results for the quarter ended June 30, 2026, reporting a 30% growth in total revenue from operations, reaching ₹6,828 million (682.8 crore) in Q1 FY2026-27. This performance was driven by continued momentum in its core therapy areas: Oncology, Biopharmaceuticals (CVRM and R&I), and Rare Disease. The company received key regulatory approvals, including for Acalabrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Mantle Cell Lymphoma, and for Trastuzumab deruxtecan in combination with pertuzumab for HER2-positive breast cancer.
Strategic initiatives during the quarter included signing a Memorandum of Understanding with the Government of Telangana for AI-enabled lung cancer screening across 20 public health facilities. The company also launched K+ Connect, a pan-India initiative for managing hyperkalaemia in heart failure and chronic kidney disease patients, and India Coronary Conquest 2026 to advance cardiovascular care.
The company received the Medical Excellence Award for its contributions to Rare Disease and was a Runner-up for its Hyperkalaemia & Kidney Care initiative at the OPPI India Awards 2026. It also received a Gold Award in the Exceptional Employee Experience in Driving Business Impact category at the ETHRWorld Employee Experience Awards 2026.
Bhavana Agrawal, Chief Financial Officer & Director, highlighted the consistent double-digit growth over the last five years and the focus on strategic investments for sustainable long-term value creation. Praveen Rao Akkinepally, Country President & Managing Director, emphasized the company's purpose of pushing the boundaries of science to deliver life-changing medicines and expand access for patients in India.
What to do with a filing like this
AstraZeneca Pharma India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by AstraZeneca Pharma India Limited. Read the original for the full detail.